H.C. Wainwright Keeps Their Buy Rating on Interpace Diagnostics Group (IDXG)


H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Interpace Diagnostics Group (IDXG) today and set a price target of $2.00. The company’s shares closed last Monday at $0.79.

According to TipRanks.com, Chen is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -26.8% and a 17.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

Currently, the analyst consensus on Interpace Diagnostics Group is a Strong Buy with an average price target of $2.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.25 and a one-year low of $0.67. Currently, Interpace Diagnostics Group has an average volume of 130K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts